{"organizations": [], "uuid": "a50281eb31e39c3a630a5b5b298b903633f1cab5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-inovio-pharmaceuticals-parker-inst/brief-inovio-pharmaceuticals-parker-institute-for-cancer-immunotherapy-establish-clinical-development-collaboration-to-evaluate-novel-cancer-immunotherapy-combinations-idUSFWN1P40DM", "country": "US", "domain_rank": 408, "title": "BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T15:24:00.000+02:00", "replies_count": 0, "uuid": "a50281eb31e39c3a630a5b5b298b903633f1cab5"}, "author": "", "url": "https://www.reuters.com/article/brief-inovio-pharmaceuticals-parker-inst/brief-inovio-pharmaceuticals-parker-institute-for-cancer-immunotherapy-establish-clinical-development-collaboration-to-evaluate-novel-cancer-immunotherapy-combinations-idUSFWN1P40DM", "ord_in_thread": 0, "title": "BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations", "locations": [], "entities": {"persons": [{"name": "parker", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-inovio pharmaceuticals", "sentiment": "neutral"}, {"name": "parker institute for cancer immunothera", "sentiment": "neutral"}, {"name": "parker institute for cancer immunotherapy establish clinical development", "sentiment": "neutral"}, {"name": "inovio pharmaceuticals inc", "sentiment": "none"}, {"name": "evaluate novel cancer immunotherapy combinations reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 25 PM / Updated 9 minutes ago BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations Reuters Staff 1 Min Read \nJan 9 (Reuters) - Inovio Pharmaceuticals Inc: \n* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS \n* INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION \n* INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF COâ€˜S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY Source text for Eikon:  ", "external_links": [], "published": "2018-01-09T15:24:00.000+02:00", "crawled": "2018-01-09T15:43:03.007+02:00", "highlightTitle": ""}